Flannery C, DeSisto A, Amani V, Venkataraman S, Lemma T, Prince W et al (2018) Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma. Oncol Rep 39(2):455–464

CAS  PubMed  Google Scholar 

Osman N, Alzobary W, Samra M, Alsaid H, Eltounsi I (2016) Lower Fas-associated phosphatase-1 expression predicted poor outcome in acute myeloid leukemia patients. Egypt J Haematol 41:111–115

Article  Google Scholar 

Kalaitzidis D, Sykes SM, Wang Z, Punt N, Tang Y, Ragu C, Sinha AU, Lane SW, Souza AL, Clish CB, Anastasiou D, Gilliland DG, Scadden DT, Guertin DA, Armstrong SA (2012) mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis. Cell Stem Cell 11:429–439

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wataya-Kaneda M (2015) Mammalian target of rapamycin and tuberous sclerosis complex. J Dermatol Sci 79(2):93–100

Article  CAS  PubMed  Google Scholar 

Kouchkovsky De and Abdul-Hay M: Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J 2016; 6, page e441

Ossenkoppele G, Schuurhuis J (2016) MRD in AML: does it already guide therapy decision-making? ASH Education Program Book 1:356–365

Google Scholar 

Récher C, Beyne-Rauzy O, Demur C, Chicanne G, Dos Santos C, Mas VM, Benzaquen D, Laurent G, Huguet F, Payrastre B (2005) Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 105(6):2527–2534

Article  PubMed  Google Scholar 

Janus A, Linke A, Cebula B, Robak T, Smolewski P (2009) Rapamycin, the mTOR kinase inhibitor, sensitizes acute myeloid leukemia cells, HL-60 cells, to the cytotoxic effect of arabinoside cytarabine. Anticancer Drugs 20:693–701

Article  CAS  PubMed  Google Scholar 

Nepstad I, Hatfield KJ, Grønningsæter IS, Reikvam H (2020) The PI3K-Akt-mTOR signaling pathway in human acute myeloid leukemia (AML) Cells. Int J Mol Sci 21(8):2907

Article  CAS  PubMed Central  Google Scholar 

Beagle B, Fruman D (2015) The PI3K-AKT-mTOR signaling network in AML. In: Andreeff M (ed) targeted therapy of acute myeloid leukemia current cancer research. Springer, New York

Google Scholar 

Murugan K, Alzahrani A, Xing M (2013) Mutations in critical domains confer the human mTOR gene strong tumorigenicity. J Biol Chem 288(9):6511–6521

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shen Y, Bai J, He A (2016) Role of mTOR signaling pathway in acute myeloid leukemia. Int J Clin Exp Med 9(2):637–647

CAS  Google Scholar 

Prabhu S, Saadat D, Zhang M, Halbur L, Fruehauf M, Ong S (2007) A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation. Oncogene 26(8):1188–1200

Article  CAS  PubMed  Google Scholar 

Hoshii T, Matsuda S, Hirao A (2014) Pleiotropic roles of mTOR complexes in haemato-lymphopoiesis and leukemogenesis. J Biochem 156(2):73–83

Article  CAS  PubMed  Google Scholar 

Kornblau SM, Tibes R, Qiu YH, Chen W, Kantarjian HM, Andreeff M, Coombes KR, Mills GB (2009) Functional proteomic profiling of AML predicts response and survival. Blood 113(1):154–164

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen W, Drakos E, Grammatikakis I, Schlette EJ, Li J, Leventaki V, Staikou-Drakopoulou E, Patsouris E, Panayiotidis P, Medeiros LJ, Rassidakis GZ (2010) mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3- mutated acute myeloid leukemia cells. Mol Cancer 9:292

Article  PubMed  PubMed Central  Google Scholar 

Heidel FH, Arreba-Tutusaus P, Armstrong SA, Fischer T (2015) Evolutionarily Conserved Signaling Pathways: Acting in the Shadows of Acute Myelogenous Leukemia’s Genetic Diversity. Clin Cancer Res 21:240–248

Article  CAS  PubMed  Google Scholar 

Darici S, Alkhaldi H, Horne G, Jørgensen HG, Marmiroli S, Huang X: Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence. J Clin Med. 2020 11;9 (9): 2934.

Gallay N, Dos Santos C, Cuzin L, Bousquet M, Simmonet Gouy V, Chaussade C, Attal M, Payrastre B, Demur C, Récher C (2009) The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia. Leukemia 23(6):1029–1038

Article  CAS  PubMed  Google Scholar